Market Intelligence, Clinical Progress, and High-Purity Reagents for Macrophage-Targeted Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD206/MRC1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD206 (MRC1) ECD-Fc Fusion Protein – Extracellular domain (aa 20-1360) containing cysteine-rich, FN-II, and CTLD domains. High purity (>95%), Endotoxin <1 EU/µg, Sequence Verified. HEK293 expressed (native glycosylation). | View CD206/MRC1 Products |
| Gene Delivery | CD206 Full-Length Lentivirus – CMV promoter-driven MRC1 ORF with GFP reporter. Enables stable cell line construction in macrophage or HEK293 background. | View CD206/MRC1 Products |
| Benchmark Ab | Anti-CD206 (MRC1) Recombinant Antibody – Sequence-verified positive control for binding, flow cytometry, and IHC validation. | View CD206/MRC1 Products |
| Validator | CD206 (MRC1) siRNA Set – Three pre-designed siRNAs targeting MRC1 for knockdown verification and specificity confirmation in cell-based assays. | View CD206/MRC1 Products |
| Related Target: CSF1R | CSF1R (c-Fms) – Master regulator of macrophage survival and differentiation; synergistic axis for TAM reprogramming studies. | View CSF1R Products |
| Related Target: CD163 | CD163 – Alternative M2 macrophage scavenger receptor; enables dual-targeting depletion strategies. | View CD163 Products |
| Related Target: CLEC10A | CLEC10A (MGL) – C-type lectin homolog for rigorous off-target counter-screening within the CLR family. | View CLEC10A Products |
| Related Target: CD11b | CD11b (ITGAM) – Myeloid lineage integrin, complementary marker for macrophage subset analysis. | View CD11b Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species translation (human/mouse/cyno) | Human, Cynomolgus, and Mouse CD206 ECD-Fc proteins available; >95% purity; Sequence Verified for ortholog epitope conservation. |
| Internalization validation for ADCs | HEK293-expressed ECD-Fc with native N-glycosylation preserves mannose-binding capacity for accurate endocytosis assays. |
| Domain-specific epitope mapping (8 CTLDs) | Isolated Carbohydrate Recognition Domain (CRD) fragments available for precise targeting of individual lectin domains. |
| Subfamily counter-screening (C-type lectin off-target) | Homolog panel (CLEC10A, CD163, CD11b) proteins strictly verified by mass spec for selectivity quantification. |
| Homology counter-screening against CD280/MRC2 | CD206-specific antigens with strict sequence divergence from CD280 to eliminate off-target binding risks. |
| Lack of robust positive controls | Sequence-verified recombinant benchmark antibodies and siRNA validators included. |
| False positives in binding | Validated siRNA sets included for definitive specificity checks in cellular models. |
Live CD206 (MRC1) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD206 (Macrophage Mannose Receptor 1 / MRC1) therapeutics is intensifying, with major players shifting focus from traditional systemic immune modulators to precise Tumor Microenvironment (TME) remodeling agents. CD206 is highly expressed on M2-like Tumor-Associated Macrophages (TAMs), making it an ideal target for selectively depleting immunosuppressive cells or delivering payloads directly to the TME. As first-generation macrophage-targeting therapies reach the clinic, the next wave of R&D is targeting highly efficient ADCs, engineered immunocytokines, and tissue-specific delivery to liver, lung, and tumor microenvironments while minimizing Kupffer cell sink effects.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugate (ADC) | Macrophage Pharma, Navidea, emerging biotechs | Solid Tumors (TAM depletion) | Internalization Assay: high-purity glycosylated ECD-Fc for pHrodo/confocal validation |
| Bispecific Macrophage Engager | Pheast Therapeutics (PHST pipeline), biotech innovators | Oncology, Fibrosis, Immunotherapy-refractory cancers | Heterodimer validation & cross-reactivity panel: species-ortholog proteins and homolog CLR antigens |
| CAR-Macrophage / Cell Therapy | Academic research groups, cell therapy innovators | Solid Tumors | Lentivirus transduction & full-length CD206 cell surface detection: full-length ORF lentivirus for stable lines |
| Monoclonal Antibody (Immunomodulation) | Undisclosed pharma pipelines | IPF, NASH, Autoimmune | Affinity tuning assay (SPR/BLI across human/cyno/mouse) to balance tumor engagement vs. liver sequestration |
| Targeted Delivery / Nanoparticles | Academic & biotech | Infectious Diseases, Fibrosis | Receptor binding & uptake: native-conformation stable cell lines via lentivirus |
Functional Domains & Key Mutations
CD206/MRC1 (UniProt P22897) contains three key functional domains: a Ricin B-type lectin domain, a Fibronectin type-II domain, and a C-type lectin 1 domain. Several clinically significant mutations have been identified: rs2296414 (dbSNP), rs606231248 (a protective factor against leprosy), and rs71497223 (dbSNP). These mutations impact receptor function and may influence drug targeting and patient stratification.
Related Targets for Macrophage Modulation
Beyond CD206, key synergistic targets in the macrophage biology panel include CSF1R (master regulator of macrophage survival), CD163 (alternative M2 marker), CLEC10A (C-type lectin homolog for off-target screening), and CD11b (myeloid lineage integrin). Combined targeting of these receptors enables comprehensive TAM phenotyping and dual-depletion strategies.